Affimed to Present at the 2018 Wells Fargo Securities Healthcare Conference
August 30 2018 - 5:33AM
Heidelberg, Germany, August 30, 2018 - Affimed
N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company
focused on discovering and developing highly targeted cancer
immunotherapies that harness the power of innate and adaptive
immunity (NK and T cells), today announced that Dr. Adi Hoess,
Affimed's CEO, will present at the 2018 Wells Fargo Securities
Healthcare Conference on Thursday, September 6, 2018 at 8:35 a.m.
ET in Boston.
A live webcast of the conference presentation
can be accessed through the "Events" section on the "Investors
& Media" page of the Affimed website at
http://www.affimed.com/events.php. A replay of the presentation
will be available from Affimed's website for 30 days following the
conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted
immunotherapies, seeking to cure patients by harnessing the power
of innate and adaptive immunity (NK and T cells). We are developing
single and combination therapies to treat cancers and other
life-threatening diseases. For more information, please visit
www.affimed.com.
Affimed Investor Contact:Gregory Gin,
Head of Investor RelationsE-Mail: IR@affimed.com
Affimed Media Contact:Anca Alexandru,
Head of Communications, EU IRE-Mail: media@affimed.com
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Affimed NV (NASDAQ:AFMD)
Historical Stock Chart
From Apr 2023 to Apr 2024